Overview
Semaglutide and Tirzepatide injections promote weight loss and may also be used to maintain a healthy weight. They work by decreasing appetite and cravings, maintaining a stable blood sugar, and slowing down the rate of digestion. Changes to diet and exercise are often combined with these medications. Both medications are administered as a once weekly subcutaneous (under the skin) injection.
Who are the best candidates for Semaglutide and Tirzepatide?
Adults who:
have a BMI greater than or equal to 30
have a BMI of 27-29 with at least one weight related condition
maintain a positive mindset during the treatment
commit to maintaining a healthy lifestyle
have realistic goals in mind for their results
What are Glucagon-like Peptide-1 Agonists?
GLP-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity.
Semaglutide
Was the first of its kind and is a safe and highly effective hormone-based weight loss medication.
Tirzepatide
Second generation GLP-1 agonist and as been shown to be even more effective in recent studies.
Health benefits associated with GLP-1 Agonists:
1.
Lower blood sugar without any increase in hypoglycemia
2.
Reduced body weight, lipids, blood pressure, inflammatory markers, and oxidative stress
3.
Suppressed appetite
4.
Enhanced insulin synthesis and secretion
5.
Reduced glucagon levels in fasting and after eating
6.
A promoted sensation of fullness in the brain
tite
7.
Slowed gastric emptying in the intestines to help you feel fuller for longer
8.
More significant improvement in cardiovascular risk factors associated with obesity
9.
Weight loss
WHAT IS SEMAGLUTIDE FOR WEIGHT LOSS?
Semaglutide is a medication that was originally developed for the treatment of type 2 diabetes. However, in recent years, it has also been studied for its potential use in weight management.
When used for weight loss, semaglutide is typically given at a higher dose than when it is used for diabetes treatment. It is given as a once-weekly injection and works by activating GLP-1 receptors in the brain, which helps to reduce appetite and increase feelings of fullness.
By reducing food intake and promoting weight loss, semaglutide may be a useful tool for people who are struggling with obesity or being overweight.
In clinical trials, semaglutide has been shown to be effective in promoting weight loss. For example, a study published in the New England Journal of Medicine in 2021 found that people who received semaglutide for 68 weeks lost an average of 15.3% of their body weight, compared to 2.4% in the placebo group.
WHAT IS TIRZEPATIDE FOR WEIGHT LOSS?
Tirzepatide is a medication that is currently being developed by Eli Lilly and Company for the treatment of type 2 diabetes, but it has also been studied for its potential use in weight management.
Similar to semaglutide, tirzepatide works by activating GLP-1 receptors in the brain, which helps to reduce appetite and increase feelings of fullness. However, tirzepatide also activates GIP receptors, which stimulates insulin secretion from the pancreas in response to food intake. By targeting both GIP and GLP-1 receptors, tirzepatide has been shown to be more effective in lowering blood sugar levels and promoting weight loss than GLP-1 receptor agonists alone.
In clinical trials, tirzepatide has shown promising results in promoting weight loss. For example, a phase II clinical trial published in The Lancet in 2021 found that people who received tirzepatide for 26 weeks lost an average of 11.3% of their body weight, compared to 2.4% in the placebo group.
In clinical trials, Semaglutide helped most recipients lose 10% of their body weight. More than half of them reduced their weight by at least 15%.
Tirzepatide, is a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. In clinical trials, participants receiving tirzepatide had a total mean weight reduction of 24.3%
click here to read the studies:
Once-weekly semaglutide in adults with overweight or obesity:
WHAT’S THE DIFFERENCE BETWEEN SEMAGLUTIDE AND TIRZEPATIDE
Semaglutide and Tirzepatide are both injectable medications used for the treatment of type 2 diabetes, but they work in slightly different ways.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means that it works by mimicking the effects of GLP-1, a hormone produced in the gut that stimulates insulin secretion, reduces glucagon secretion, and slows down gastric emptying. By activating GLP-1 receptors, semaglutide helps to lower blood sugar levels and promote weight loss.
Tirzepatide, on the other hand, is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. In addition to activating GLP-1 receptors like Semaglutide, it also activates GIP receptors, which stimulates insulin secretion from the pancreas in response to food intake. By targeting both GIP and GLP-1 receptors, Tirzepatide has been shown to be more effective in lowering blood sugar levels and promoting weight loss than GLP-1 receptor agonists alone.
In terms of dosing, Semaglutide is available in a once-weekly injectable form, while tirzepatide is also a once-weekly injectable medication. However, Tirzepatide comes in higher doses than semaglutide, and it has been shown to be more effective at lowering blood sugar levels and promoting weight loss in clinical trials.
Overall, both Semaglutide and Tirzepatide are effective medications for the treatment of type 2 diabetes, but they work through different mechanisms and have different dosing requirements. The choice between the two medications may depend on the individual patient’s needs and preferences, as well as their response to the medication.
What are contraindications to Semaglutide and Tirzepatide?
-
Do not use Semaglutide or Tirzepatide if you or anyone in your family has ever had a rare type of thyroid cancer known as Medullary Thyroid Carcinoma
-
Do not use Semaglutide or Tirzepatide if you have Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
-
Do not use Semaglutide or Tirzepatide if you have had an allergic reaction to either medications
-
Do not use Semaglutide or Tirzepatide if you are pregnant or breastfeeding.
What are the side effects of Semaglutide and Tirzepatide?
The most common side effects are GI related. Constipation and some underlying queasiness are common when you first start the medication, and each time you go up in dosing. Sometimes, pt’s will report moderate nausea the week after starting Semaglutide or Tirzepatide. We prescribe medications to help reduce or eliminate side effects